Lines are open Mon-Fri 08:00 - 18:00
A new take on an existing medication has been successfully tested for men suffering from premature ejaculation, showing positive results in its clinical trial in Europe.
Ampio Pharmaceuticals Inc has announced significant success of one of their upcoming treatments, Zertane, during a third phase trial to assist men with premature ejaculation.
This “new” drug contains the active ingredient tramadol hydrochloride, which has previously been used as a pain relief after development in the 1970’s, but has now been redesigned by Ampio for treatment of PE.
The pharmaceutical company, which specialises in innovating existing treatments for different conditions, said that “the analysis of the trail results exceeded [their] expectations”. While exact details on how Zertane will contribute in the body to combating premature ejaculation, the chemical tramadol hydrochloride is known to release serotonin.
This neurotransmitter, which is found naturally in the central nervous system and often referred to as the “happiness hormone”, regulates mood, appetite and sleep; all of which could potentially play a role in the management of ejaculation.
If approved by European and United Kingdom regulators, the EMA and MHRA respectively, the drug would be intended for use before intercourse much like impotence and erectile dysfunction treatments. At present Ampio suggests that over 23% of men between the ages of 18 and 75 suffer to a degree of premature ejaculation.
It’s still not known if Zertane will be put forward for approval and marketing in the United States from the FDA after it has finished clinical trials in Europe.